Inhibikase Therapeutics (IKT) Other Working Capital Changes (2020 - 2026)
Inhibikase Therapeutics (IKT) posted quarterly Other Working Capital Changes of $60638.0 for Q1 2026, up 110.27% quarter-over-quarter from -$590645.0 in Q4 2025.
Inhibikase Therapeutics (IKT) Other Working Capital Changes (2020 - 2026) Analysis & Trends
Inhibikase Therapeutics (IKT) has reported Other Working Capital Changes for 7 consecutive years, with $60638.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Working Capital Changes changed N/A year-over-year to $60638.0; the TTM figure through Mar 2026 stood at -$472094.0 (down 510.58% YoY), while the FY2025 annual figure was -$532732.0, down 510.74% from the prior year.
- Other Working Capital Changes rose to $60638.0 in Q1 2026 per IKT's latest filing, from -$590645.0 in the prior quarter.
- Across five years, Other Working Capital Changes topped out at $759312.0 in Q1 2023 and bottomed at -$590645.0 in Q4 2025.
- Historically, Other Working Capital Changes has averaged -$13841.6 across 5 years, with a median of -$6912.5 in 2022.
- On a YoY basis, Other Working Capital Changes climbed as much as 324.88% in 2023 and fell as far as 17238400.0% in 2023.
- Inhibikase Therapeutics' Other Working Capital Changes stood at -$13824.0 in 2022, then plunged by 601.81% to -$97018.0 in 2023, then jumped by 233.69% to $129702.0 in 2024, then sank by 555.39% to -$590645.0 in 2025, then jumped by 110.27% to $60638.0 in 2026.
- Business Quant data shows IKT's Other Working Capital Changes at $60638.0 in Q1 2026, -$590645.0 in Q4 2025, and -$14660.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Inhibikase Therapeutics | 420.72 Mn | 261.70 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -358,875.00 |
| Jun 30, 2026 | -358,875.00 |
| Jun 30, 2026 | -358,875.00 |
| Mar 31, 2026 | 60,638.00 |
| Mar 31, 2026 | 60,638.00 |
| Mar 31, 2026 | 60,638.00 |
| Dec 31, 2025 | -590,645.00 |
| Dec 31, 2025 | -590,645.00 |
| Dec 31, 2025 | -590,645.00 |
| Sep 30, 2025 | -14,660.00 |
| Sep 30, 2025 | -14,660.00 |
| Sep 30, 2025 | -14,660.00 |
| Jun 30, 2025 | 72,573.00 |
| Jun 30, 2025 | 72,573.00 |
| Jun 30, 2025 | 72,573.00 |
| Dec 31, 2024 | 129,702.00 |
| Dec 31, 2024 | 129,702.00 |
| Dec 31, 2024 | 129,702.00 |
| Sep 30, 2024 | -62,389.00 |
| Sep 30, 2024 | -62,389.00 |